Abstract
The amyloid cascade hypothesis is well known hypothesis describing the pathogenesis of Alzheimers disease (AD). On the basis of this hypothesis, inhibition of amyloid β-protein (Aβ) generation and aggregation, enhancement of extracellular Aβ removal, and Aβ vaccination are currently under investigation. Intracellular Aβ may be even more important than extracellular Aβ, since intraneuronal Aβ accumulation commonly precedes extracellular Aβ deposition in several familial AD-related mutant presenilin 1-transgenic mice. Various pathogenic mechanisms involving intracellular Aβ such as mitochondrial toxicity, proteasome impairment and synaptic damage have been suggested. Recently, we have reported that cytosolic Aβ42 accumulation leads to p53 mRNA expression and p53-related apoptosis. It was also reported that a novel chaperone protein, Aβ-related death-inducing protein (AB-DIP), regulates nuclear localization of intracellular Aβ42. Therefore, intraneuronal Aβ represents an alternative therapeutic target. While inhibition of Aβ production and anti-Aβ immunotherapies are likely to attenuate both intraneuronal and extracellular Aβ toxicity, more specific antiintraneuronal Aβ therapies should be useful. The focus of this article is to review the pathogenic mechanisms involving intracellular Aβ and advocate intracellular Aβ as an important therapeutic target in AD.
Keywords: Alzheimer's disease, amyloid β-protein, Aβ-related death-inducing protein, p53, apoptosis, proteasome
Current Alzheimer Research
Title: Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease
Volume: 5 Issue: 6
Author(s): Y. Ohyagi
Affiliation:
Keywords: Alzheimer's disease, amyloid β-protein, Aβ-related death-inducing protein, p53, apoptosis, proteasome
Abstract: The amyloid cascade hypothesis is well known hypothesis describing the pathogenesis of Alzheimers disease (AD). On the basis of this hypothesis, inhibition of amyloid β-protein (Aβ) generation and aggregation, enhancement of extracellular Aβ removal, and Aβ vaccination are currently under investigation. Intracellular Aβ may be even more important than extracellular Aβ, since intraneuronal Aβ accumulation commonly precedes extracellular Aβ deposition in several familial AD-related mutant presenilin 1-transgenic mice. Various pathogenic mechanisms involving intracellular Aβ such as mitochondrial toxicity, proteasome impairment and synaptic damage have been suggested. Recently, we have reported that cytosolic Aβ42 accumulation leads to p53 mRNA expression and p53-related apoptosis. It was also reported that a novel chaperone protein, Aβ-related death-inducing protein (AB-DIP), regulates nuclear localization of intracellular Aβ42. Therefore, intraneuronal Aβ represents an alternative therapeutic target. While inhibition of Aβ production and anti-Aβ immunotherapies are likely to attenuate both intraneuronal and extracellular Aβ toxicity, more specific antiintraneuronal Aβ therapies should be useful. The focus of this article is to review the pathogenic mechanisms involving intracellular Aβ and advocate intracellular Aβ as an important therapeutic target in AD.
Export Options
About this article
Cite this article as:
Ohyagi Y., Intracellular Amyloid β-Protein As a Therapeutic Target for Treating Alzheimers Disease, Current Alzheimer Research 2008; 5 (6) . https://dx.doi.org/10.2174/156720508786898514
DOI https://dx.doi.org/10.2174/156720508786898514 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease
Current Alzheimer Research Central Nervous System Disorders Associated to Immune Checkpoint Inhibitors
Current Cancer Therapy Reviews Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Exposure to Perinatal Infections and Bipolar Disorder: A Systematic Review
Current Molecular Medicine Retroperitoneal Cryptococcoma in a Case of Disseminated Cryptococcosis on Antifungal Maintenance Therapy
Current HIV Research Immunotherapy, Vascular Pathology, and Microhemorrhages in Transgenic Mice
CNS & Neurological Disorders - Drug Targets Lymphocytic Choriomeningitis Virus Infection: Neglected Teratogenic Zoonosis
Current Women`s Health Reviews Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Current Therapeutic Options for Alzheimers Disease
Current Genomics Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS
Current Pharmaceutical Design Effective Antiviral Medicinal Plants and Biological Compounds Against Central Nervous System Infections: A Mechanistic Review
Current Drug Discovery Technologies Future Targeted Disease Modifying Drugs for Alzheimer's Disease
Recent Patents on CNS Drug Discovery (Discontinued) Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
Current Alzheimer Research Pan-Amyloid Oligomer Specific scFv Antibody Attenuates Memory Deficits and Brain Amyloid Burden in Mice with Alzheimer’s Disease
Current Alzheimer Research Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design
Medicinal Chemistry